Table 7.
Model Generated from Pre-screened Predictors
| Effect | Estimate | Standardized Est |
|---|---|---|
| Intercept | 4.268844 | 0 |
| Baseline Visit Count | 0.001667 | 0.01991 |
| Baseline Primary Care Visit Count | 0.000924 | 0.00261 |
| Baseline Occupational Visit Count | 0.011031 | 0.016 |
| Bupropion Rx in Baseline (Y/N) | 0.052414 | 0.00666 |
| Non-Opioid Analgesics Rx Count (CN103) | 0.003163 | 0.00798 |
| Anti-rheumatics, Other Rx Count (MS190) | -0.000129 | -0.00032 |
| Sedative/Hypnotics, Other Rx Count (CN309) | 0.00711 | 0.0054 |
| Tricyclic Antidepressants Rx Count (CN601) | 0.002659 | 0.00374 |
| Local Anesthetics, Topical Rx Count (DE700) | 0.026352 | 0.00779 |
| Soaps/Shampoos/Soap-Free Cleansers Rx Count (DE400) | 0.012432 | 0.00283 |
| Decongestants, Systemic Rx Count (RE200) | 0.055989 | 0.01166 |
| Distinct VA Drug Class Rx | 0.014658 | 0.06702 |
| Joint Injection Count | 0.003921 | 0.00196 |
| Days End of Prednisone | -0.000913 | -0.09852 |
| Baseline PDC for Etanercept | -0.131689 | -0.01788 |
| Days Start of Golimumab | -0.000651 | -0.00439 |
| Baseline PDC for Non-Biologic DMARDs | -0.672468 | -0.1552 |
| Start Methotrexate in 14 Days after Index Date (Y/N) | 0.04705 | 0.00697 |
| Start Leflunomide in 14 Days after Index Date (Y/N) | 0.013983 | 0.00113 |
| Start in TNFi Biologic DMARDs in 14 Days after Index Date (Count of distinct Rx) | 0.471838 | 0.05367 |
| Start in Non-Biologic DMARDs in 14 Days after Index Date (Count of distinct Rx) | 0.364512 | 0.09201 |
| Start in Steroid in 14 Days after Index Date (Count of distinct Rx) | 0.175888 | 0.02539 |
| Varicose Veins of Lower Extremity (CCS119) | 0.020937 | 0.00268 |
| Disease of Mouth Excluding Dental Dx Count in Baseline (CCS137) | 0.064254 | 0.00581 |
| Other Connective Tissue Disease Dx Count in Baseline (CCS211) | 0.003949 | 0.00625 |
| Disease of White Blood Cells Dx Count in Baseline (CCS63) | 0.066725 | 0.01247 |
| Conditions Associated With Dizziness or Vertigo Dx Count in Baseline (CCS93) | 0.013165 | 0.0045 |
| Baseline Lab test for Chem Panel (Y/N) | -0.378938 | -0.02308 |
| Baseline Lab test for RF (Y/N) | 0.001583 | 0.00051 |
| Baseline Foot Surgery (Y/N) | 0.019935 | 0.00611 |
| Baseline Hand Surgery (Y/N) | 0.10473 | 0.02932 |
| Opioid Analgesics Rx (Y/N) | 0.190656 | 0.06105 |
| Non-Opioid Analgesics Rx (CN103) (Y/N) | 0.070215 | 0.02137 |
| Tricyclic Antidepressants Rx (CN601) (Y/N) | 0.098618 | 0.01553 |
| Antidepressants, Other Rx (CN609) (Y/N) | 0.064811 | 0.01974 |
| CNS Medications, Other Rx (CN900) (Y/N) | 0.095795 | 0.00729 |
| Loop Diuretics Rx (CV702) (Y/N) | 0.084218 | 0.01669 |
| Diagnostics, Other Rx (DX900) (Y/N) | 0.15962 | 0.03678 |
| Insulin Rx (HS501) (Y/N) | 0.013138 | 0.00212 |
| Thyroid Supplements Rx (HS851) (Y/N) | 0.02656 | 0.00532 |
| Antigout Agents Rx (MS400) (Y/N) | 0.003596 | 0.00046 |
| Baseline Occupational Visit (Y/N) | 0.052566 | 0.01056 |
| Start in Non-Biologic DMARDs in 14 Days after Index Date (Y/N) | 0.357809 | 0.0783 |
| Start in DMARDs in 14 Days after Index Date (Y/N) | 0.834045 | 0.11812 |
| Baseline Use of Sulfasalazine (Y/N) | 0.157077 | 0.03865 |
| Baseline Use of Rituximab (Y/N) | 0.08026 | 0.00625 |